Search results
Showing 16 to 30 of 371 results for hypertension
Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)
Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.
This indicator covers the contractor establishing and maintaining a register of patients with established hypertension. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM239
Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)
Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.
View recommendations for HTG662Show all sections
Hypertension: confirming diagnosis with HBPM or ABPM (IND115)
This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (HTG410)
Evidence-based recommendations on balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension in adults. This involves inserting and inflating a balloon in blocked blood vessels in the lungs to improve blood flow.
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
This indicator covers the percentage of patients with hypertension aged 16 to 74 years in whom there is an annual assessment of physical activity, using GPPAQ, in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM36
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension (HTG741)
Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal nerves.
View recommendations for HTG741Show all sections
Hypertension: urinary albumin for target organ damage (IND121)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of urinary albumin: creatinine ratio test in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM75
Hypertension: brief intervention to increase physical activity (IND96)
This indicator covers the percentage of patients with hypertension aged 16 or over and who have not attained the age of 75 who score ‘less than active’ on GPPAQ in the preceding 15 months, who also have a record of a brief intervention in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM37
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Evidence-based recommendations on telemetric adjustable pulmonary artery banding for reducing pulmonary hypertension in infants with congenital heart defects. This involves placing a remote-controlled band around the pulmonary artery that can be tightened or loosened to control blood flow.
Alcohol use: risk assessment for people with hypertension (IND196)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after the date of entry on the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved